KRT17: The Hidden Protein Driving Cancer Therapy Resistance Explained

29 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Discover how the protein KRT17 (Keratin 17) has emerged as a key player in cancer drug resistance across multiple cancer types — including bladder, breast, cervical, colorectal, and pancreatic cancers.
In this video, we break down:
- What KRT17 is and why it matters in cancer biology.
- How KRT17 promotes chemotherapy and immunotherapy resistance.
- The signaling pathways involved (AKT/ERK, Wnt/β-catenin, FAK/SRC/ERK, and more).
- Its dual immunomodulatory role — both suppressive and activating depending on cancer type.
- Why KRT17 is a promising therapeutic target and biomarker for precision oncology.
If you’re a cancer researcher, oncologist, or student interested in molecular oncology, you’ll gain insight into how understanding KRT17 can lead to next-generation cancer treatment strategies.
Keywords: KRT17, cancer therapy resistance, biomarkers, precision medicine, oncology research, immunotherapy, targeted therapy, tumor microenvironment, epithelial-mesenchymal transition (EMT), molecular mechanisms of resistance.
Categoria
Oncology
Commenta per primo questo video.

Prossimo